Capital Cell

Capital Cell (legal name PFP CAPITAL CELL S.L.) is an active EU-based equity crowdfunding platform headquartered in Barcelona, Spain. It specialises in early-stage biotechnology and life sciences investments and is authorised by the Spanish Securities Market Commission (CNMV) under the European Crowdfunding Service Providers regulation (ECSP) [1][2]. The platform reports having completed 161 funding rounds and approximately €153 million invested, with a reported portfolio value multiplier of 2.7x on its website (figures shown on the platform) [2].

Why this matters: the CNMV authorisation confirms that Capital Cell operates under EU crowdfunding rules rather than UK FCA rules, which has direct consequences for the regulatory protections available to UK investors [1][4].

Capital Cell lists and vets early-stage life sciences companies for equity raises, presenting opportunities to individual investors who can commit capital online. The platform states that funds are held and released according to the terms of each round and that funding is only released once the target is met, consistent with standard crowdfunding mechanics [2].

Selection and due diligence. Capital Cell describes a screening process and industry review for projects; third-party write-ups reference a specialised expert network and a selective acceptance rate, but the exact membership and the 3% acceptance figure are not corroborated on the primary site excerpts provided here and should be treated as unverified unless the platform publishes a detailed methodology [2][unverified].

Why this matters: investors should know that platform screening does not eliminate high failure risk in early-stage biotech — due diligence and understanding of scientific and regulatory hurdles remain essential.

Asset class. Equity in unlisted early-stage healthtech and biotech companies (pre-seed to seed+). Platform materials and public pages indicate a specialised focus on biotech/life sciences [2].

• Minimums. Some third-party summaries suggest minimum investments can be relatively low (e.g. €100–€1,000), but the platform's current public pages should be checked for each offer because minimums are set per project and are not consistently confirmed in the provided sources [unverified].
• Fees. External summaries report an 8% commission charged to companies on capital raised and an SPV management fee schedule (annual fees of approximately €3,084 to €9,000 depending on amount raised). These fees are commonly cited in market write-ups but are not clearly documented in the primary site excerpts provided here and should be verified directly with Capital Cell before relying on them [5][unverified].
• Retraction/withdrawal. The platform references a short investor withdrawal (retraction) window common in EU crowdfunding (for example, a 7-day period is mentioned in third-party materials), but investors should confirm the exact cooling-off and cancellation mechanics for each round in the offer documents [2][unverified].
• Secondary market. Capital Cell references mechanisms for investor-to-investor transfers in certain cases; the degree to which this provides reliable liquidity is limited and typically requires negotiation between investors [unverified].

Why this matters: fee structures, minimums and secondary market rules materially affect net returns and the ability to exit — confirm these details on each offer's documentation before investing.

Capital Cell is aimed at investors seeking exposure to early-stage biotechnology and life sciences companies and who understand and accept high risk, long holding periods and potential total loss of capital [2]. It is not suited for investors seeking liquid, short-term returns.

Why this matters: the investor profile determines suitability — early-stage biotech requires patience, sector knowledge or willingness to accept specialist risk, and a capacity to bear losses.

Strengths.

• Sector focus. Offers direct access to a specialist asset class (biotech/life sciences) that can be difficult for private investors to access through other routes [2].
• Documented activity. The platform reports multiple completed rounds and a meaningful aggregate invested amount, which demonstrates operational scale in its niche [2].

Risks.

• Regulatory scope. Capital Cell is CNMV-authorised under the ECSP, not authorised by the UK FCA. UK investors therefore generally would not have access to the UK Financial Services Compensation Scheme (FSCS) or the UK Financial Ombudsman Service for disputes involving the platform [1][4]. This does not mean the platform is illegal in the UK, but it changes the regulatory protections available to UK-based investors.
• Investment risk and liquidity. Investments are in early-stage biotech companies — high failure rates, long development and regulatory timelines, high burn rates and very limited liquidity mean investors should expect to hold positions for several years and potentially lose their capital [2].
• Track record vs cash returns. Site-reported portfolio multipliers (e.g. 2.7x) refer to portfolio valuation metrics; historical cash distributions and realised exits have been limited, and some analyses show few cash outflows relative to the number of investments — investors should distinguish between paper value (unrealised) and actual cash returns when assessing performance [2][unverified].

Regulatory status.

• Capital Cell (PFP CAPITAL CELL S.L.) is authorised by the Spanish CNMV as a Participatory Financing Service Provider under Regulation (EU) 2020/1503 (ECSP) — this is the firm's primary regulator [1].
• The firm is not listed as directly authorised by the UK Financial Conduct Authority (FCA) and no UK Firm Reference Number (FRN) for Capital Cell was found in the FCA register search included in the research [4].

Implications for UK investors. If you are a UK resident using an ECSP-authorised platform that is not FCA-authorised, UK regulatory protections such as FSCS compensation and the UK Financial Ombudsman Service will typically not apply to the platform itself. UK investors should consider whether the platform's governance, custody arrangements and complaints process meet their expectations before investing [1][4].

Complaints procedure. Capital Cell publishes a complaints and grievances procedure and provides contact routes (e.g. email) for registered complaints; it aims to resolve complaints within stated internal timeframes, but investors should retain documentation and consider local dispute-resolution options if necessary [6].

• No UK FCA authorisation. For UK investors this is the most important watch point — review the implications for compensation and dispute resolution carefully [1][4].
• Realised exits vs paper value. Reported portfolio valuation multiples are not the same as realised cash returns; historical cash distributions have been limited relative to the scale of investments — treat valuation multiples as informative but not equivalent to guaranteed returns [2][unverified].
• Limited public reviews. Public platforms for user feedback show relatively few consumer reviews, which makes gauging user experience more difficult; absence of complaints publicly does not imply absence of issues [unverified].